Biogen Idec Refocusing On U.S. Avonex Sales While Awaiting Tysabri's Fate
This article was originally published in The Pink Sheet Daily
Executive Summary
Multiple sclerosis product is up 10%, driven by European sales, but the U.S. market remains disappointing.